News Release
 View printer-friendly version |
| << Back |
| StemCells, Inc. Reports Fourth Quarter and Fiscal 2009 Financial Results |
| PALO ALTO, Calif., Mar 11, 2010 (GlobeNewswire via COMTEX) -- StemCells, Inc. (Nasdaq:STEM) today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.
For the fourth quarter of 2009, the Company reported a net loss of $5,234,000, or $(0.05) per share, compared with a net loss of $10,082,000, or $(0.11) per share, for the fourth quarter of 2008. Loss from operations was $8,081,000, compared to $7,098,000 for the same period of 2008. Total revenue was $418,000, compared to $172,000 for the same period of 2008. The growth in revenue in the fourth quarter of 2009 compared to the same period of 2008 was primarily due to the consolidation of the SCS operations, which included the addition of product sales revenue from the Company's SC Proven(R) portfolio of specialty cell culture products. For the full year 2009, the Company reported a net loss of $27,026,000, or $(0.25) per share, compared with a net loss of $29,087,000, or $(0.35) per share, for 2008. Loss from operations was $29,378,000, compared to $26,738,000 for 2008. Total revenue was $993,000, a 328% increase over total revenue of $232,000 reported in 2008. This increase was primarily due to the SCS operations, which included a total of $385,000 in product sales from the SC Proven business for the period April 1 to December 31, 2009. Total operating expenses in 2009 were $30,110,000, compared to $26,970,000 in 2008. Approximately 80%, or $2,537,000, of the increase in 2009 was due to the SCS operations. Operating expenses in 2009 also included two non-recurring items: (i) transaction expenses of $693,000 related to the SCS acquisition, and (ii) a charge of $310,000 to set up a reserve for expenses associated with the Company's exit from its Melbourne, Australia site. Excluding these non-recurring items and the expenses associated with the SCS operations, operating expenses were essentially unchanged compared to 2008. For the full year 2009, the Company recorded other income of $1,899,000 due to a decrease in warrant liability, while in 2008 the Company recorded a charge of $937,000 to reflect an increase in warrant liability. In 2008, the Company also recorded a charge of $2,083,000 to write down the value of its investment in marketable equity securities. There was no such write down in 2009. For the full year 2009, cash used in operations totaled $24,683,000, compared to $22,740,000 in 2008. At December 31, 2009, the Company's cash, cash equivalents and marketable debt securities totaled $38,618,000. Highlights for 2009 and significant recent events since the end of the year include: Clinical Development
-- In January 2009, we completed a Phase I clinical trial of our
HuCNS-SC(R) product candidate (purified human neural stem cells) in
infantile and late infantile neuronal ceroid lipofuscinosis (NCL, also
often referred to as Batten disease), a fatal neurodegenerative disorder
in children.
-- In June 2009, we announced positive results from our NCL trial. The
Phase I data demonstrated that the HuCNS-SC cells, the transplantation
procedure, and the immunosuppression regimen were well tolerated, and
that the patients' medical, neurological and neuropsychological
conditions, following transplantation, appeared consistent with the
normal course of the disease. In addition to this favorable safety
profile, we reported evidence of engraftment and long-term survival of
the HuCNS-SC cells.
-- In November 2009, we met with the U.S. Food and Drug Administration
(FDA) to review the results of our NCL trial and to discuss our proposed
clinical development plans. During this meeting, the FDA acknowledged
our position that the risk-benefit profile shown by the Phase I data
merits further clinical evaluation of HuCNS-SC cells in NCL. We continue
to be in discussions with the FDA regarding our plans for a second NCL
trial.
-- In November 2009, we initiated a Phase I clinical trial designed to test
the safety and preliminary efficacy of our HuCNS-SC cells in
Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder that
primarily afflicts infants and young children. This study, which is the
second clinical trial of our HuCNS-SC cells in a neurodegenerative
disease, is being conducted at the University of California, San
Francisco (UCSF) Children's Hospital.
-- In February 2010, we enrolled and treated the first patient in our PMD
trial, marking the first time that neural stem cells have been
transplanted as a potential treatment for a myelination disorder. We
expect it will take 12-18 months to complete enrollment in this trial.
Preclinical Development
-- In May 2009, our collaborators at Oregon Health & Science University
(OHSU) Casey Eye Institute presented data showing that our human neural
stem cells, when transplanted into an animal model of retinal
degeneration, engraft long term and protect the retina from progressive
degeneration. Retinal degeneration leads to loss of vision in diseases
such as age-related macular degeneration (AMD). These findings were
presented at the Association for Research in Vision and Ophthalmology
2009 Annual Meeting.
-- In September 2009, our preclinical data demonstrating proof-of-concept
of our HuCNS-SC cells in NCL was published in the peer-reviewed journal
Cell Stem Cell. Our human neural stem cells, when transplanted in a
mouse model of infantile NCL, were shown to engraft, migrate throughout
the brain and continuously secrete the missing lysosomal enzyme
characteristic of NCL. Moreover, mice transplanted with our neural stem
cells showed statistically significant reduction in cellular waste
build-up, protection of critical host neurons and delayed loss of motor
function compared with the control (non-transplanted) group.
-- In September 2009, we received ethics committee approval at the
Universite Catholique de Louvain (UCL) in Belgium to initiate a clinical
study evaluating our human liver engrafting cells (hLEC) as a potential
cellular therapy for liver-based metabolic disorders. However, we have
decided to defer initiating a clinical study of hLEC pending additional
refinements to our process of isolating and purifying these cells.
-- In October 2009, our collaborators at OHSU Casey Eye Institute presented
preclinical data showing that our human neural stem cells, in an animal
model of retinal degeneration, protect cone photoreceptors (cones) from
progressive degeneration and preserve visual function long term. Cones
are light sensing cells that are highly concentrated within the macula
of the human eye. The ability to protect these cells suggests a
promising approach to treating AMD, the leading cause of vision loss and
blindness in people over the age of 55. These findings were presented at
the Society for Neuroscience 2009 Annual Meeting.
Enabling Technologies
-- In April 2009, we closed the acquisition of substantially all of the
operating assets and liabilities of SCS for 2,650,000 shares of our
common stock and approximately $700,000 in cash. As a result of this
transaction, we added proprietary cell technologies relating to
embryonic stem cells, induced pluripotent stem (iPS) cells, and
tissue-derived (adult) stem cells; expertise and infrastructure for
providing cell-based assays for drug discovery; a specialty cell culture
products business; an intellectual property portfolio with claims
relevant to cell processing, reprogramming and manipulation, as well as
to gene targeting and insertion; and a European presence with operations
in Cambridge, UK.
-- In September 2009, we announced organizational initiatives focused on
growing our SC Proven cell culture products business and advancing the
development and commercialization of cell-based assay platforms for use
in drug discovery and development. These initiatives included new
personnel appointments and a realignment of activities within our
Cambridge, UK and Palo Alto, California locations, as well as the
wind-down of our operations in Melbourne, Australia.
-- In January 2010, we launched GS1-RTM, the first commercially available
medium to enable the derivation, maintenance and growth of true
(germline competent) rat embryonic stem cells. GS1-R is expected to have
significant utility in the creation of genetically engineered rat models
of human disease for use in academic, medical and pharmaceutical
research.
-- In February 2010, we launched GS2-MTM, a new cell culture medium that
enables the derivation and long-term maintenance of true mouse iPS
cells. GS2-M has been shown to increase the efficiency of reprogramming
'pre-iPS' cells to derive fully pluripotent stem cells, and to maintain
mouse iPS cells in a pluripotent state in long-term culture.
Intellectual Property and Licensing Activities
-- In April 2009, we announced that a major international pharmaceutical
company acquired a non-exclusive license to our Internal Ribosome Entry
Site (IRES) technology, which was acquired as part of the SCS
operations. The IRES technology enables researchers to genetically
modify any mammalian cell and to monitor the activity of a particular
gene of interest without blocking the normal function of the gene. The
IRES technology is particularly important for evaluating the success of
gene knock-outs or knock-ins in stem cells, as well as for the
successful creation of genetically engineered mouse and rat models of
human disease.
-- In May 2009, the U.S. Patent and Trademark Office (PTO) upheld the
validity of our two remaining neural stem cell patents that were
subjected to reexamination proceedings commenced by Neuralstem, Inc.
The decision by the PTO to uphold the two patents is final and cannot be
appealed. A total of five patents were reexamined in proceedings
requested by Neuralstem, and the validity of all five has been upheld by
the PTO. Four of the upheld patents are the subject of litigation
initiated by us against Neuralstem, in which we allege various unfair
competition torts and infringement of a total of six patents. These six
patents collectively claim the manufacture and use of human neural stem
and progenitor cells as tools for drug discovery and as therapeutic
agents. In August 2009, the court approved a scheduling order for
discovery and trial.
-- In December 2009, we received a Notice of Allowance and a Notice of
Issuance from the PTO for two patents claiming technologies for the
establishment and maintenance of cell pluripotency, including the
reprogramming of cells to create pluripotent stem cells. These patents
strengthen our intellectual property position in both the embryonic stem
cell and iPS cell fields.
Financing and Stock-related Activities
-- In June 2009, we were added to the Russell 3000(R) Index, a broad market
index that measures the performance of the 3000 largest companies in the
United States. We are also included in the Russell 2000(R) Index, which
is a subset of the Russell 3000 representing the small capitalization
segment of the U.S. equity market.
-- In November 2009, we raised $12,500,000 in gross proceeds through the
sale of 10,000,000 shares of common stock and warrants to purchase four
million shares of common stock at an exercise price of $1.50 per share.
We received total proceeds, net of offering expenses and placement
agency fees, of approximately $11,985,000.
"2009 was a watershed year for StemCells," said Martin McGlynn, President and CEO of StemCells, Inc. "With our SCS acquisition, we took an important step towards our strategic objective of building a sustainable business that has the dual focus of stem cell therapeutics and enabling technologies for use in stem cell research. With regard to the latter, we are currently marketing our SC Proven specialty cell culture products, and we anticipate continued strong growth in this business in the coming year. We are also pursuing opportunities to leverage our core competencies in the development of stem cell-based assays for drug discovery. In our therapeutic programs, we are very encouraged by the positive safety profile of our HuCNS-SC cells demonstrated in our NCL trial, and we are working diligently to advance our programs in additional indications. "Economic and financial conditions remain challenging. We continue to proactively control our operating expenses and cash burn, and despite market volatility, we successfully raised $30 million in 2009, which enables us to remain focused on the execution of our strategic agenda." About StemCells, Inc. StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and enabling technologies for use in stem cell-based research and drug discovery. In its cellular medicine programs, StemCells is targeting diseases of the central nervous system and liver. StemCells' lead product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven(R) brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and over 200 granted or allowed non-U.S. patents. Further information about StemCells is available at www.stemcellsinc.com. The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014 Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the "Company"); the prospect and timing associated with completing the Company's PMD trial the prospect for continued clinical development of the Company's HuCNS-SC cells in NCL and in other diseases; the prospect for growth in the Company's SC Proven business; and the Company's ability to commercialize drug discovery and drug development tools. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties with respect to the fact that additional trials will be required to confirm the safety and demonstrate the efficacy of the Company's HuCNS-SC cells for the treatment of NCL or any other disease; risks whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in NCL, PMD or in future clinical trials of proposed therapies for other diseases or conditions; uncertainties about the design of future clinical trials and whether the Company will receive the necessary support of a clinical trial site and its institutional review board to pursue future clinical trials in NCL, PMD or in proposed therapies for other diseases or conditions; uncertainties regarding the potential for the Company to grow its SC Proven business and to advance the development and commercialization of cell-based assays for drug discovery and development; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations, including such operations of the Company for non-therapeutic applications, and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding whether results in preclinical research in animals will be indicative of future clinical results in humans; uncertainties regarding the Company's manufacturing capabilities given its increasing preclinical and clinical commitments; uncertainties regarding the validity and enforceability of the Company's patents; uncertainties as to whether the Company will become profitable; and other factors that are described under the heading "Risk Factors" disclosed in Part I, Item 1A in the Company's Annual Report on Form 10-K for the year ended December 31, 2009.
StemCells, Inc.
Unaudited Condensed
Consolidated Statement of
Operations
(in thousands, except share and
per share amounts)
(unaudited)
Three months ended Twelve months ended
December 31 December 31
------------------------- -------------------------
2009 2008 2009 2008
------------ ----------- ------------ -----------
Revenue:
Revenue from licensing
agreements and grants $ 308 $ 172 $ 608 $ 232
Revenue from product sales 110 -- 385 --
------------ ----------- ------------ -----------
Total revenue 418 172 993 232
Cost of product sales (60) -- (261) --
------------ ----------- ------------ -----------
Gross profit 357 172 732 232
Operating expenses:
Research and development 5,651 4,721 19,930 17,808
Selling, general and
administrative 2,678 2,064 9,530 8,296
Wind-down expenses 110 485 650 866
------------ ----------- ------------ -----------
Total operating expenses 8,438 7,270 30,110 26,970
------------ ----------- ------------ -----------
Loss from operations (8,081) (7,098) (29,378) (26,738)
Other income (expense):
Other than temporary impairment
of marketable securities -- (2,083) -- (2,083)
Realized gain on sale of
marketable securities 9 -- 407 --
Change in fair value of
warrant liability 2,721 (937) 1,899 (937)
Interest income (expense), net (14) 39 (43) 693
Other income (expense), net 131 (4) 90 (22)
------------ ----------- ------------ -----------
Total other income (expense),
net 2,847 (2,985) 2,352 (2,349)
------------ ----------- ------------ -----------
Net loss $ (5,234) $ (10,082) $ (27,026) $ (29,087)
============ =========== ============ ===========
Basic and diluted net loss per
share $ (0.05) $ (0.11) $ (0.25) $ (0.35)
============ =========== ============ ===========
Shares used to compute basic
and diluted loss per share 114,870,995 88,343,325 106,045,961 82,716,455
============ =========== ============ ===========
StemCells, Inc.
Unaudited Condensed
Consolidated Balance Sheets
(in thousands)
December
December 31, 2008
31, 2009 (a)
----------- -----------
(unaudited) (unaudited)
ASSETS:
Current Assets:
Cash & cash equivalents $ 38,618 $ 30,043
Marketable securities 197 4,182
Other current assets 1,326 1,107
----------- -----------
Total current assets 40,141 35,332
Property, plant and
equipment, net 2,857 3,173
Goodwill and other
intangible assets, net 5,667 646
Other assets, non-current 2,525 2,079
----------- -----------
Total assets $ 51,190 $ 41,230
=========== ===========
LIABILITIES AND
STOCKHOLDERS' EQUITY:
Current liabilities 6,530 5,318
Fair value of warrant
liability 9,677 8,440
Other non-current
liabilities 4,488 5,663
Stockholders' equity 30,495 21,809
----------- -----------
Total liabilities and
stockholders' equity $ 51,190 $ 41,230
=========== ===========
(a) Derived from audited financial statements included in StemCells' annual report on form 10-K filed with the SEC. This news release was distributed by GlobeNewswire, www.globenewswire.com SOURCE: StemCells, Inc. CONTACT: StemCells, Inc. Investor Inquiries Megan Meloni (650) 475-3100, ext. 105 Vida Communication, Inc. Media Tim Brons (415) 675-7402 |
